$ZTS
Zoetis Inc.

2023 Q4 Form 10-Q Financial Statement

#000155528023000247 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $2.213B $2.151B
YoY Change 8.48% 7.44%
Cost Of Revenue $726.0M $638.0M
YoY Change 11.52% 5.11%
Gross Profit $1.487B $1.513B
YoY Change 7.06% 8.46%
Gross Profit Margin 67.19% 70.34%
Selling, General & Admin $565.0M $525.0M
YoY Change 9.92% 4.79%
% of Gross Profit 38.0% 34.7%
Research & Development $174.0M $152.0M
YoY Change 17.57% 13.43%
% of Gross Profit 11.7% 10.05%
Depreciation & Amortization $126.0M $124.0M
YoY Change 5.88% 7.83%
% of Gross Profit 8.47% 8.2%
Operating Expenses $754.0M $677.0M
YoY Change 9.12% 6.61%
Operating Profit $733.0M $836.0M
YoY Change 5.01% 10.0%
Interest Expense -$39.00M $59.00M
YoY Change -32.76% 11.32%
% of Operating Profit -5.32% 7.06%
Other Income/Expense, Net -$6.000M
YoY Change -300.0%
Pretax Income $650.0M $717.0M
YoY Change 9.8% 7.5%
Income Tax $127.0M $121.0M
% Of Pretax Income 19.54% 16.88%
Net Earnings $525.0M $596.0M
YoY Change 13.88% 12.67%
Net Earnings / Revenue 23.72% 27.71%
Basic Earnings Per Share $1.29
Diluted Earnings Per Share $1.14 $1.29
COMMON SHARES
Basic Shares Outstanding 459.1M shares 460.3M shares
Diluted Shares Outstanding 461.4M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.039B $1.751B
YoY Change -43.0% -30.04%
Cash & Equivalents $2.041B $1.754B
Short-Term Investments
Other Short-Term Assets $434.0M $467.0M
YoY Change 18.9% -15.4%
Inventory $2.564B $2.744B
Prepaid Expenses
Receivables $1.304B $1.257B
Other Receivables $58.00M $0.00
Total Short-Term Assets $6.343B $6.222B
YoY Change -15.49% -5.02%
LONG-TERM ASSETS
Property, Plant & Equipment $3.204B $3.092B
YoY Change 16.38% 17.88%
Goodwill $2.759B $2.762B
YoY Change 0.47% 2.6%
Intangibles $1.338B $1.398B
YoY Change -3.04% 5.99%
Long-Term Investments
YoY Change
Other Assets $206.0M $216.0M
YoY Change 40.14% 34.16%
Total Long-Term Assets $7.957B $7.884B
YoY Change 7.61% 10.68%
TOTAL ASSETS
Total Short-Term Assets $6.343B $6.222B
Total Long-Term Assets $7.957B $7.884B
Total Assets $14.30B $14.11B
YoY Change -4.03% 3.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $411.0M $388.0M
YoY Change 1.48% 4.02%
Accrued Expenses $683.0M $977.0M
YoY Change 0.15% 4.38%
Deferred Revenue
YoY Change
Short-Term Debt $3.000M $2.000M
YoY Change 50.0% -33.33%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.889B $1.608B
YoY Change -40.35% -44.17%
LONG-TERM LIABILITIES
Long-Term Debt $6.564B $6.552B
YoY Change 0.18% 25.76%
Other Long-Term Liabilities $237.0M $259.0M
YoY Change 9.22% 8.37%
Total Long-Term Liabilities $6.801B $6.811B
YoY Change 0.47% 25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.889B $1.608B
Total Long-Term Liabilities $6.801B $6.811B
Total Liabilities $9.295B $9.032B
YoY Change -11.66% 0.22%
SHAREHOLDERS EQUITY
Retained Earnings $10.30B $10.14B
YoY Change 18.77% 18.83%
Common Stock $5.000M $5.000M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.597B $5.369B
YoY Change 23.31% 29.72%
Treasury Stock Shares
Shareholders Equity $4.997B $5.078B
YoY Change
Total Liabilities & Shareholders Equity $14.29B $14.11B
YoY Change -4.28% 3.16%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $525.0M $596.0M
YoY Change 13.88% 12.67%
Depreciation, Depletion And Amortization $126.0M $124.0M
YoY Change 5.88% 7.83%
Cash From Operating Activities $897.0M $724.0M
YoY Change 21.05% 37.64%
INVESTING ACTIVITIES
Capital Expenditures $198.0M $145.0M
YoY Change 15.79% -194.16%
Acquisitions
YoY Change
Other Investing Activities -$12.00M -$126.0M
YoY Change -95.51% -520.0%
Cash From Investing Activities -$210.0M -$271.0M
YoY Change -52.05% 118.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -397.0M -416.0M
YoY Change -150.9% -21.36%
NET CHANGE
Cash From Operating Activities 897.0M 724.0M
Cash From Investing Activities -210.0M -271.0M
Cash From Financing Activities -397.0M -416.0M
Net Change In Cash 290.0M 37.00M
YoY Change -73.22% -129.13%
FREE CASH FLOW
Cash From Operating Activities $897.0M $724.0M
Capital Expenditures $198.0M $145.0M
Free Cash Flow $699.0M $579.0M
YoY Change 22.63% -14.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 zts Restructuring Charges And Acquisition Related Costs
RestructuringChargesAndAcquisitionRelatedCosts
16000000 usd
CY2022Q3 zts Restructuring Charges And Acquisition Related Costs
RestructuringChargesAndAcquisitionRelatedCosts
6000000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
467000000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
365000000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
6222000000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7506000000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2529000000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2297000000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3092000000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2753000000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
220000000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
2762000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
2746000000 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1398000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1380000000 usd
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
190000000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
173000000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
216000000 usd
CY2023Q3 us-gaap Assets
Assets
14106000000 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
2000000 usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
2000000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1350000000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
97000000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
97000000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1608000000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3167000000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6552000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6552000000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
160000000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
142000000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
191000000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
186000000 usd
CY2023Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
262000000 usd
CY2022Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
258000000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
259000000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
217000000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
9032000000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
10522000000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6000000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
501891243 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
501891243 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
459524713 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
463808059 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5000000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000000 usd
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
38083184 shares
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
5369000000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4539000000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1116000000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1088000000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
10140000000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
8668000000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-814000000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5078000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4405000000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-4000000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-2000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4403000000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14106000000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14925000000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
3000000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
4000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4621000000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
596000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
81000000 usd
CY2023Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
252000000 usd
CY2022Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
377000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4662000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4403000000 usd
us-gaap Profit Loss
ProfitLoss
1817000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
61000000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
864000000 usd
us-gaap Dividends Common Stock
DividendsCommonStock
346000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5074000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4544000000 usd
us-gaap Profit Loss
ProfitLoss
1651000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-45000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5000000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1189000000 usd
zts Contributed Capital Associatedwith Pension To Be Contributedby Related Party
ContributedCapitalAssociatedwithPensionToBeContributedbyRelatedParty
2000000 usd
us-gaap Dividends Common Stock
DividendsCommonStock
306000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4662000000 usd
us-gaap Profit Loss
ProfitLoss
1817000000 usd
us-gaap Profit Loss
ProfitLoss
1651000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
365000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
346000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
43000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
46000000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
27000000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
7000000 usd
zts Gain On Sale Of Business Excluding Transaction Costs
GainOnSaleOfBusinessExcludingTransactionCosts
118000000 usd
zts Gain On Sale Of Business Excluding Transaction Costs
GainOnSaleOfBusinessExcludingTransactionCosts
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
82000000 usd
us-gaap Inventory Write Down
InventoryWriteDown
49000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-40000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-110000000 usd
zts Non Cash Transfersto Related Party
NonCashTransferstoRelatedParty
0 usd
zts Non Cash Transfersto Related Party
NonCashTransferstoRelatedParty
2000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
54000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
120000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1171000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
534000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
415000000 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
155000000 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
96000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
3000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8000000 usd
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-23000000 usd
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-74000000 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
96000000 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-567000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-445000000 usd
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
0 usd
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
3000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1350000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3581000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3485000000 usd
CY2023Q3 zts Numberof Regional Segments
NumberofRegionalSegments
2 geographicregion
CY2023Q3 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
45 country
CY2023Q3 zts Number Of Core Animal Species Marketed
NumberOfCoreAnimalSpeciesMarketed
8 specie
CY2023Q3 zts Number Of Major Product Categories
NumberOfMajorProductCategories
7 productcategory
CY2023Q3 zts Number Of Major Product Lines
NumberOfMajorProductLines
300 product_category
CY2023Q3 us-gaap Revenues
Revenues
2151000000 usd
CY2022Q3 us-gaap Revenues
Revenues
2002000000 usd
us-gaap Revenues
Revenues
6331000000 usd
CY2023Q3 us-gaap Revenues
Revenues
2151000000 usd
CY2022Q3 us-gaap Revenues
Revenues
2002000000 usd
us-gaap Revenues
Revenues
6331000000 usd
us-gaap Revenues
Revenues
6040000000 usd
CY2023Q3 us-gaap Revenues
Revenues
2151000000 usd
CY2022Q3 us-gaap Revenues
Revenues
2002000000 usd
us-gaap Revenues
Revenues
6331000000 usd
us-gaap Revenues
Revenues
6040000000 usd
CY2023Q3 us-gaap Revenues
Revenues
2151000000 usd
CY2022Q3 us-gaap Revenues
Revenues
2002000000 usd
us-gaap Revenues
Revenues
6331000000 usd
us-gaap Revenues
Revenues
6040000000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4000000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14000000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147000000 usd
CY2022Q4 us-gaap Assets
Assets
14925000000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-817000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5074000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5074000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4580000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
528000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-87000000 usd
CY2022Q3 zts Contributed Capital Associatedwith Pension To Be Contributedby Related Party
ContributedCapitalAssociatedwithPensionToBeContributedbyRelatedParty
1000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
497000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
438000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
119000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
20000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-59000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-27000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-227000000 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-8000000 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
41000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1456000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
3000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
zts Share Based Compensation Related Proceeds Net Of Taxes Paid On Withholding Shares
ShareBasedCompensationRelatedProceedsNetOfTaxesPaidOnWithholdingShares
18000000 usd
zts Share Based Compensation Related Proceeds Net Of Taxes Paid On Withholding Shares
ShareBasedCompensationRelatedProceedsNetOfTaxesPaidOnWithholdingShares
-38000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
857000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1189000000 usd
us-gaap Payments Of Ordinary Dividends
PaymentsOfOrdinaryDividends
520000000 usd
us-gaap Payments Of Ordinary Dividends
PaymentsOfOrdinaryDividends
460000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2712000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1684000000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-20000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1827000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-978000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1754000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
586000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
471000000 usd
us-gaap Interest Paid Net
InterestPaidNet
225000000 usd
us-gaap Interest Paid Net
InterestPaidNet
209000000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
42000000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
37000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5000000 usd
zts Excise Tax Accrued On Net Share Repurchased Not Paid
ExciseTaxAccruedOnNetShareRepurchasedNotPaid
7000000 usd
zts Excise Tax Accrued On Net Share Repurchased Not Paid
ExciseTaxAccruedOnNetShareRepurchasedNotPaid
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
74000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
46000000 usd
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2000000 usd
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 usd
CY2023Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
4000000 usd
CY2022Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
1000000 usd
us-gaap Nature Of Operations
NatureOfOperations
<div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. Organization </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. We organize and operate our business in two geographic regions: the United States (U.S.) and International. </span></div>We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical products, anti-infectives, animal health diagnostics and medicated feed additives.
us-gaap Revenues
Revenues
6040000000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13000000 usd
CY2023Q3 zts Gain Loss On Disposition Of Business Remeasurement Of Retained Noncontrolling Investment
GainLossOnDispositionOfBusinessRemeasurementOfRetainedNoncontrollingInvestment
24000000 usd
us-gaap Business Exit Costs1
BusinessExitCosts1
4000000 usd
us-gaap Business Exit Costs1
BusinessExitCosts1
1000000 usd
CY2023Q3 zts Restructuring Charges And Acquisition Related Costs
RestructuringChargesAndAcquisitionRelatedCosts
16000000 usd
CY2022Q3 zts Restructuring Charges And Acquisition Related Costs
RestructuringChargesAndAcquisitionRelatedCosts
6000000 usd
zts Restructuring Charges And Acquisition Related Costs
RestructuringChargesAndAcquisitionRelatedCosts
45000000 usd
zts Restructuring Charges And Acquisition Related Costs
RestructuringChargesAndAcquisitionRelatedCosts
9000000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
15000000 usd
us-gaap Restructuring Charges
RestructuringCharges
38000000 usd
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
1000000 usd
zts Restructuring Reserve Utilization And Other
RestructuringReserveUtilizationAndOther
18000000 usd
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
34000000 usd
CY2023Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1000000 usd
CY2022Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1000000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
36000000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
3000000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
13000000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
79000000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20000000 usd
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
6000000 usd
CY2022Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1000000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
17000000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1000000 usd
CY2023Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1000000 usd
CY2022Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1000000 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0 usd
CY2023Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2022Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
101000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-19000000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-41000000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-36000000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6000000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
151000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6000000 usd
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.169
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.208
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.205
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.200
CY2023Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
30000000 usd
CY2023Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
190000000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
160000000 usd
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
31000000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
173000000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
142000000 usd
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
202000000 usd
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
27000000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
194000000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
19000000 usd
CY2023Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
50000000 usd
CY2023Q3 us-gaap Commercial Paper
CommercialPaper
0 usd
CY2022Q4 us-gaap Commercial Paper
CommercialPaper
0 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6650000000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
-62000000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1350000000 usd
CY2022Q4 us-gaap Hedged Liability Fair Value Hedge Cumulative Increase Decrease
HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
-32000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6552000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1350000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
750000000 usd
CY2023Q3 zts Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
4550000000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6650000000 usd
us-gaap Interest Expense
InterestExpense
159000000 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
16000000 usd
us-gaap Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
114000000 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
6000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1158000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2650000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1445000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1205000000 usd
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
240000000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1090000000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
825000000 usd
CY2022Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
430000000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
2345000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
2746000000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
38000000 usd
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
-7000000 usd
us-gaap Goodwill Other Increase Decrease
GoodwillOtherIncreaseDecrease
-15000000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
2762000000 usd
CY2023Q3 us-gaap Goodwill Gross
GoodwillGross
3298000000 usd
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
3282000000 usd
CY2022Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
536000000 usd
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
536000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2718000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1560000000 usd
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
240000000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
175000000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
175000000 usd
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
2958000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1560000000 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1398000000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
2825000000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1445000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1380000000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
141000000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
147000000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17000000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46000000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
271150 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
162.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
43.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0384
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0092
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.2863
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y2M12D
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6000000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000000 shares
CY2023Q3 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
1700000000 shares
CY2023Q3 us-gaap Profit Loss
ProfitLoss
596000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
528000000 usd
us-gaap Profit Loss
ProfitLoss
1817000000 usd
us-gaap Profit Loss
ProfitLoss
1651000000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
596000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
529000000 usd
us-gaap Net Income Loss
NetIncomeLoss
1819000000 usd
us-gaap Net Income Loss
NetIncomeLoss
1653000000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
460300000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
467800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
461900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
470000000.0 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1100000 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1300000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1100000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1600000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
461400000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
469100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
463000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
471600000 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.52
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.51
CY2019Q3 zts Number Of Multinational Companies
NumberOfMultinationalCompanies
39 companies
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
B. Guarantees and IndemnificationsIn the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 30, 2023, recorded amounts for the estimated fair value of these indemnifications were not material.
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
717000000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
667000000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
124000000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
115000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2286000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2064000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
365000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
346000000 usd
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001555280-23-000247-index-headers.html Edgar Link pending
0001555280-23-000247-index.html Edgar Link pending
0001555280-23-000247.txt Edgar Link pending
0001555280-23-000247-xbrl.zip Edgar Link pending
a10qex311q32023.htm Edgar Link pending
a10qex312q32023.htm Edgar Link pending
a10qex321q32023.htm Edgar Link pending
a10qex322q32023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zts-20230930.htm Edgar Link pending
zts-20230930.xsd Edgar Link pending
zts-20230930_cal.xml Edgar Link unprocessable
zts-20230930_def.xml Edgar Link unprocessable
zts-20230930_lab.xml Edgar Link unprocessable
zts-20230930_pre.xml Edgar Link unprocessable
zts-20230930_htm.xml Edgar Link completed